drugset
Drugs / levophed
last change Oct 2022 re-read 9 days ago

levophed

also known as Noradrenaline Bitartrate
Developed for
ischemic stroke · acute hypotension · traumatic brain injury
Investigated by
Johns Hopkins University · National Institutes of Health (NIH)

Regulatory milestones approvals, filings & regulatory actions · 1 recorded

MilestoneJurisdictionBrandIndicationDateSentence it was read from
Approved US (FDA) LEVOPHED — 1950-07-13 fda.gov ↗

Trials 1

today
US approved 1950
NCT00227448 · Ph 2
194919501951195219531954195519561957195819591960196119621963196419651966196719681969197019711972197319741975197619771978197919801981198219831984198519861987198819891990199119921993199419951996199719981999200020012002200320042005200620072008200920102011201220132014201520162017201820192020202120222023202420252026202720282029
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 21 trial
Phase 2 NCT00227448 Jun 2003 → Apr 2005 ischemic stroke Johns Hopkins University Completed No outcome recorded
Comparator or background therapy2 trials
Phase 4 NCT05502146 Comparator Aug → Oct 2022 acute hypotension, local anesthetic poisoning Mersin University Completed No outcome recorded
— NCT00795366 Comparator Sep 2008 → Sep 2014 traumatic brain injury University of Miami Completed No outcome recorded

Evidence & citations 4 cited values

Every value below carries the sentence it was read from. 3 sources stand behind the page.

FieldValueCited text
Known as levophed “levophed, dopamine, phenylephrine)” NCT00795366 ↗
1

NCT00227448 ↗
Known as Noradrenaline Bitartrate ClinicalTrials.gov intervention name — accepted as the source's own label NCT05502146 ↗
Action Activate “Norepinephrine is an alpha adrenergic agonist with weak beta adrenergic agonistic activity” NCT05502146 ↗
Route Intravenous “intravenous levophed” NCT00227448 ↗